ReviewHemodialysis international. International Symposium on Home Hemodialysis2026
Recent Progress in Double Filtration Plasmapheresis.
Review in Hemodialysis international. International Symposium on Home Hemodialysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Marked Clinical Improvement in Parkinson's Disease Following Double-Filtration Apheresis: A Case Report.Degenerative neurological and neuromuscular disease · 2026Article
- Recent Progress in Double Filtration Plasmapheresis.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- Clinical, laboratory, and histopathological characteristics of pediatric lupus nephritis: a retrospective study in a national referral center in Mexico.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Double-filtration plasmapheresis is an advanced extracorporeal blood purification technique that selectively removes pathogenic macromolecules based on molecular weight. Unlike conventional plasma exchange, double-filtration plasmapheresis uses a two-step filtration process to retain beneficial plasma components such as albumin, while eliminating harmful substances, thereby reducing the need for exogenous plasma replacement. Over the last few decades, double-filtration plasmapheresis has gained prominence in the management of refractory autoimmune, neurological, metabolic, and renal diseases. This review systematically examines the therapeutic mechanisms, recent clinical advances, safety, limitations, and prospects of double-filtration plasmapheresis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.